Novartis Pharmaceuticals — Clinical Trial Pipeline

Novartis Pharmaceuticals has 18 registered trials in the index.

Trials (18)

• Non-small Cell Lung Cancer Registry Phase 4 · Novartis Pharmaceuticals
• Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma Phase 1 · Novartis Pharmaceuticals
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Phase 1 · Novartis Pharmaceuticals
• A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence N/A · Novartis Pharmaceuticals
• Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Phase 1/2 · Novartis Pharmaceuticals
• Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation Phase 3 · Novartis Pharmaceuticals
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma Phase 2 · Novartis Pharmaceuticals
• Managed Access Programs for LDK378, Ceritinib N/A · Novartis Pharmaceuticals
• First in Human Trial of TAS266 in Patients With Advanced Solid Tumors Phase 1 · Novartis Pharmaceuticals
• Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy Phase 2 · Novartis Pharmaceuticals
• Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. Phase 2 · Novartis Pharmaceuticals
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Phase 3 · Novartis Pharmaceuticals
• Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer Phase 1/2 · Novartis Pharmaceuticals
• Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy Phase 3 · Novartis Pharmaceuticals
• A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors Phase 2 · Novartis Pharmaceuticals
• A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia Phase 2 · Novartis Pharmaceuticals
• Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Phase 1 · Novartis Pharmaceuticals
• Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer Phase 4 · Novartis Pharmaceuticals

Related landscapes

• Carcinoma, Non-Small-Cell Lung
• Non-Small-Cell Lung Cancer
• Pleural Effusion, Malignant
• Mesothelioma
• Melanoma

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.